NTLA-2003

N/A

Report date: 2024/09/29 15:35:51

Base Information

Drug NameNTLA-2003
Drug Alias NameNTLA2003NTLA-2003
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionAlpha-1-antiproteinase inhibitorsGene expression modulators
TargetsAlpha-1-antiproteinase
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIntellia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIntellia Therapeutics Inc
Active IndicationsN/A
Inactive Indicationsalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksN/A